role in the pathogenesis of atrial fibrillation. Other risk factors include excess alcohol intake, tobacco smoking, diabetes mellitus, and thyrotoxicosis. However, about half of cases are...
The landscape for stroke prevention in atrial fibrillation has been changed by the availability of the direct oral anticoagulants (DOACs) that have been tested in large, prospective, randomized tri...
Anticoagulation in atrial fibrillation. by Benjamin A Steinberg, Jonathan P Piccini. BMJ (Clinical research ed.). Read more related scholarly scientific articles and abstracts.
This editorial refers to ‘Anticoagulation with edoxaban in patients with long atrial high-rate episodes ≥24 h’, by N. Becher et al., https://doi.org/10.1093/eur
Oral anticoagulation in nonvalvular atrial fibrillation
The therapeutic dilemma between rhythm and rate control in the management of atrial fibrillation (AF) is still unresolved and electrical or pharmacological cardioversion (CV) frequently represents...
Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been ...
It is uncertain whether bridging anticoagulation is necessary for patients with atrial fibrillation who need an interruption in warfarin treatment for an elective operation or other elective invasi...
Atrial fibrillation increases the risk of stroke, which is a leading cause of death and disability worldwide. The use of oral anticoagulation in patients with atrial fibrillation at moderate or hig...
The ORBIT Bleeding Risk Score for Atrial Fibrillation predicts bleeding risk in patients on anticoagulation for afib, similar to HAS-BLED.